Entities / Company
Gilgamesh Pharmaceuticals.
American pharmaceutical company
- Reports this week
- 0
- Active events
- 0
- Connections
- 2
What's happening
Gone quiet
No new reports in 90+ days-
AbbVie is transitioning from legacy drugs to newer blockbusters, acquiring psychedelic drug candidates, and expanding API manufacturing capacity.Some support2 reports2 developments inside
-
AbbVie acquired Gilgamesh Pharmaceuticals' psychedelic drug program, with analysts noting the sector is nearing a tipping point.Some support2 reports
-
AbbVie acquired Gilgamesh's pipeline drug while FDA leadership shifts weighed on deal-making among major pharmaceutical companies.Well supported5 reports
-
Gilgamesh Pharmaceuticals acquired Bretisilocin, adding depth to Neuro's drug development pipeline.Some support1 report
No events began in the chosen period. Widen it, or reset.
Around Gilgamesh Pharmaceuticals this week
News at the entities that move Gilgamesh Pharmaceuticals most-
AbbVie TransactionalAbbVie and Cerevel Therapeutics successfully launched a new drug for Parkinson's disease, pending government coverage negotiations.Moves Gilgamesh Pharmaceuticals
Connections
The 1 strongest of 2, analyzed from the reporting. The bars show how strongly a change on one side reaches the other.-
AbbVie Transactional
AbbVie has repeatedly acquired drug programs and candidates from Gilgamesh Pharmaceuticals.
History
Events by the month they beganJune 2026
4 events- AbbVie is transitioning from legacy drugs to newer blockbusters, acquiring psychedelic drug candidates, and expanding API manufacturing capacity.
- AbbVie acquired Gilgamesh Pharmaceuticals' psychedelic drug program, with analysts noting the sector is nearing a tipping point.
- AbbVie acquired Gilgamesh's pipeline drug while FDA leadership shifts weighed on deal-making among major pharmaceutical companies.
- Gilgamesh Pharmaceuticals acquired Bretisilocin, adding depth to Neuro's drug development pipeline.